Is Semax legal in the US?
The short answer
Semax is not an FDA-approved drug and is not on the 503A Bulks List as of 2026-07-28. On 2026-07-24, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it — but that vote is advisory. FDA must still complete rulemaking before anything changes.
The July 23-24, 2026 vote
Caveat on this number: Reported as 8-5. Unofficial webcast transcription indicated one abstention; no official FDA record confirms it.
What FDA actually evaluated
FDA assessed Semax for one thing: cerebral ischemia, migraine and trigeminal neuralgia.
FDA did not review Semax for cognition, focus, nootropic use, ADHD or athletic performance — the uses it is most often marketed for online.
Full regulatory status
| FDA-approved drug? | No FDA-approved US drug contains Semax. Intranasal Semax products have been registered outside the United States, including in Russia — that is not FDA approval. |
|---|---|
| Indication FDA reviewed | Cerebral ischemia, migraine and trigeminal neuralgia |
| PCAC recommendation | Recommended for the 503A Bulks List (advisory only) |
| FDA reviewers' position | Do not add to the 503A Bulks List. |
| Category 2 status | Previously in FDA's interim Category 2 (significant safety risk). Moved to the “nominated but withdrawn” table after the nomination was withdrawn in April 2026. Removal from Category 2 did not authorize compounding and did not move it to Category 1. |
| 503A Bulks List today | Not on the 503A Bulks List. A PCAC recommendation is advisory only — FDA must complete rulemaking before 21 CFR 216.23 changes. |
| 503B status | Not on the final 503B Bulks List, and not in FDA's published interim 503B categories. |
| Prescription status | No FDA-approved US status. Registration in another country does not create US prescription or OTC status. |
| Next federal event | Possible rulemaking. No Semax-specific date has been announced. |
If you compete in sport
No substance-specific WADA or USADA determination was found. Not being named is not the same as being permitted.
We could not find a substance-specific ruling. Treat this as unknown, not as permission, and check with your governing body before use.
Why FDA's own reviewers recommended against it
- Inconsistent characterization
- Inadequate impurity, aggregate, microbial and endotoxin controls
- Missing formulation, solubility and nasal-delivery-device information
- Immunogenicity uncertainty
- Very limited, small, uncontrolled or incompletely reported clinical studies
- No adequate evidence for subcutaneous use
- Possible bleeding or antithrombotic concerns
- Approved alternatives available for all three nominated conditions
What you can actually do today
You can seek clinical assessment and discuss approved treatments for ischemic disease, migraine or trigeminal neuralgia. The vote did not approve Semax for those uses.
What would have to happen for this to change
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Sources
See the status of all seven peptides side by side in the FDA 503A compounding tracker.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.